pharma
Amazon and Novartis team up on cloud services
December 5, 2019Sales and Marketing Amazon Web Services, Cloud services, Novartis, amazon, pharma, product lines
Novartis is teaming up with Amazon Web Services to utilise its cloud computing technology. The collaboration is designed to overhaul …
Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine
December 5, 2019Research and Development Allergan, FDA, pharma, ubrogepant
New Phase 3 data has been released showing that both 50mg and 100mg doses of Allergan’s ubrogepant met their primary …
Patient experience: Living with desmoid fibromatosis
December 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing desmoid fibrosis, feature, patient experience, pharma, rare disease
Lisa Pascoe lives with a rare, benign desmoid tumour in her abdomen. She opens up to Pharmafocus on her diagnosis …
Roche’s Tecentriq combo scores FDA approval in non-small cell lung cancer
December 4, 2019Research and Development, Sales and Marketing FDA, NSCLC, Roche, pharma, tecentriq
Roche’s immunotherapy Tecentriq (atelizumab) has chalked up another approval from the FDA, this time in combination with the chemotherapy Abraxane …
AstraZeneca sells US/Canada rights for Seroquel for $41 million to “focus on main therapy areas”
December 3, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, pharma
AstraZeneca has announced its intention to jettison the rights to two non-core drugs in the US and Canada in order …
Astellas poised to acquire neuromuscular disease specialist Audentes for $3bn all-cash
December 3, 2019Manufacturing and Production, Sales and Marketing Astellas, Audentes, acquisition, neuromuscular disease, pharma
Astellas Pharma is set to acquire US-based Audentes Therapeutics in an all-cash deal valued at $3 billion in cash, it …
Exclusive interview: Samsung Bioepis’ Sang-Jin Pak on the rise of biosimilars
December 2, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Samsung Bioepis, biosimilars, pharma
Following on from our focus on biosimilars in our feature last week, you can read Nikhil Patel’s interview with Sang-Jin …
NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases
December 2, 2019Sales and Marketing Cancer, NHS, NICE, lynparza, ovarian cancer, pharma
NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s …
Roche’s satralizumab shows promise at Phase 3 in neuromyelitis optica spectrum disorder
December 2, 2019Research and Development, Sales and Marketing Roche, pharma, satralizumab
Roche has presented new data on its interleukin-6 (IL-6) inhibitor satralizumab in the treatment of neuromyelitis optica spectrum disorder (NMOSD), …
Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund
November 28, 2019Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma
Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …
Corbyn reveals documents showing US-UK meetings on deregulating NHS drug pricing
November 27, 2019Research and Development, Sales and Marketing Jeremy Corbyn, Labour Party, NHS, US, pharma
Labour Leader Jeremy Corbyn has showed off documents that detail secret trade meetings between the US and UK Governments, where …
New ICER report reveals most cost-effective rheumatoid arthritis therapies
November 27, 2019Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma
The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
Europe approves first subcutaneous version of biosimilar infliximab
November 26, 2019Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma
The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …
The coming age of biosimilars
November 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, feature, pharma
With more and more biosimilars securing approval and the sheer potential value they have to offer for healthcare systems around …
Novartis acquires The Medicines Company in a deal worth $9.7 billion
November 25, 2019Sales and Marketing Novartis, The Medicines Company, pharma
Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously …
Latest content
Five Facts about cardiovascular disease
